These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046 [TBL] [Abstract][Full Text] [Related]
4. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice. Yamagishi A; Ikekubo Y; Mishina M; Ikeda K; Ide S J Pharmacol Sci; 2024 Mar; 154(3):203-208. PubMed ID: 38395521 [TBL] [Abstract][Full Text] [Related]
5. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of ketamine action as an antidepressant. Zanos P; Gould TD Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791 [TBL] [Abstract][Full Text] [Related]
8. Antidepressant-relevant concentrations of the ketamine metabolite (2 Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190 [TBL] [Abstract][Full Text] [Related]
9. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Hashimoto K Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725 [TBL] [Abstract][Full Text] [Related]
11. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. Shirayama Y; Hashimoto K Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993 [TBL] [Abstract][Full Text] [Related]
12. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218 [TBL] [Abstract][Full Text] [Related]
13. CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity. Nguyen TML; McGowan JC; Gardier AM Neuropharmacology; 2022 Mar; 206():108936. PubMed ID: 34965407 [TBL] [Abstract][Full Text] [Related]
14. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761 [TBL] [Abstract][Full Text] [Related]
15. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360 [TBL] [Abstract][Full Text] [Related]
16. Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action. Aleksandrova LR; Wang YT; Phillips AG Chronic Stress (Thousand Oaks); 2017; 1():. PubMed ID: 30556028 [TBL] [Abstract][Full Text] [Related]
17. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886 [TBL] [Abstract][Full Text] [Related]
18. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model. Zhang K; Fujita Y; Hashimoto K Sci Rep; 2018 Mar; 8(1):4007. PubMed ID: 29507385 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Hashimoto K Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141 [TBL] [Abstract][Full Text] [Related]